推薦產品
化驗
≥98% (TLC)
形狀
powder
光學活性
[α]25/D -5.4°, c = 4.9 in 1 M HCl(lit.)
顏色
white to off-white
mp
202-203 °C (lit.)
溶解度
H2O: soluble
ethanol: soluble
&epsilon ；(消光係數)
8,700 at 294 nm at 1 M
起源
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES 字串
[H]\C(=C(/[H])C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2
InChI
1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1
InChI 密鑰
WLRMANUAADYWEA-NWASOUNVSA-N
基因資訊
human ... ADRB1(153) , ADRB2(154) , ADRB3(155)
尋找類似的產品？ 前往 產品比較指南
應用
Timolol maleate has been used as an adrenergic β-blocker for evaluating cardiovascular functions in mice5. It has also been used for evaluating the uptake of 86Rb+ in rat cardiomyocytes6.
生化／生理作用
Timolol maleate is a class II anti-arrhythmic agent that functions as a non-selective β-adrenoceptor antagonist, a vasodilator and an anti-glaucoma agent. Studies have reported that timolol maleate can be used for the treatment of infantile hemangioma (IH)7.
特點和優勢
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Timolol maleate is soluble in ethanol and water.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Repr. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
個人防護裝備
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
客戶也查看了
Hsien Chan et al.
Pediatrics, 131(6), e1739-e1747 (2013-05-08)
Timolol maleate 0.5% gel is a safe and effective medication for treating superficial infantile hemangiomas (IHs) in infants with a median age of 9 weeks. Forty-one infants who had superficial IHs without ulceration and not near mucosal surfaces were recruited
H Viko et al.
Pharmacology & toxicology, 76(1), 68-71 (1995-01-01)
The present study was undertaken to develop an improved and stabilized method for isolating cardiomyocytes from perfused rat heart. Different lots of the commercial collagenases used for isolating cardiomyocytes give variable results both with respect to the total cell yield
Hyun Jung Jung et al.
Journal of controlled release : official journal of the Controlled Release Society, 165(1), 82-89 (2012-11-06)
Glaucoma is the second major cause of blindness in the world after cataract. Glaucoma management through eye drops that reduce the intraocular pressure (IOP) has major deficiencies including low patient compliance and low bioavailability. Extended wear contact lenses that deliver
Sveinn Hakon Hardarson
Acta ophthalmologica, 91 Thesis 2, 1-47 (2013-03-09)
ABSTRACT.: Malfunction of retinal blood flow or oxygenation is believed to be involved in various diseases. Among them are retinal vessel occlusions, diabetic retinopathy and glaucoma. Reliable, non-invasive technology for retinal oxygen measurements has been scarce and most of the
M Gallarate et al.
International journal of pharmaceutics, 440(2), 126-134 (2012-10-20)
After an initial screening of ingredients and production methods, nanoemulsions for ocular administration of timolol containing the drug as maleate (TM) or as ion-pair with AOT (TM/AOT) were prepared. The physico-chemical characterization of nanoemulsions, regarding mean diameter, pH, zeta potential
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
